Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

Sergio Buccheri; Giovanna Sarno; David Erlinge; Henrik Renlund; Bo Lagerqvist; Per Grimfjärd; Nils Witt; Troels Yndigegn; Ole Fröbert; Jonas Persson; Felix Böhm; Stefan James

doi:10.4244/EIJ-D-20-00429

Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

Sergio Buccheri, Giovanna Sarno, David Erlinge, Henrik Renlund, Bo Lagerqvist, Per Grimfjärd, Nils Witt, Troels Yndigegn, Ole Fröbert, Jonas Persson, Felix Böhm, Stefan James

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

9 Citations (Scopus)

Abstract

Aims: The aim of this study was to assess the real-world clinical performance of a sirolimus-eluting ultrathin-strut drug-eluting stent (DES) (Orsiro) in a large nationwide cohort of patients undergoing percutaneous coronary intervention (PCI). Methods and results: From the Swedish Coronary Angiography and Angioplasty Registry, the two-year outcomes of 4,561 patients implanted with Orsiro (Orsiro group) and 69,570 receiving other newer-generation DES (n-DES group) were analysed. The rate of definite stent thrombosis was low in both groups (0.67% and 0.83% for Orsiro and n-DES, respectively; adjusted hazard ratio [HR] 0.90, 95% confidence interval [CI]: 0.55-1.46, p-value 0.66). Restenosis was also infrequent (1.5% vs 2.0% with Orsiro and n-DES, adjusted HR 0.81, 95% CI: 0.63-1.03, p-value=0.09). The risk of target lesion revascularisation by PCI was lower in the Orsiro group (1.6% vs 2.3%, adjusted HR 0.75, 95% CI: 0.60-0.94, p-value=0.013). All-cause mortality and myocardial infarction did not show a statistically significant difference between the two groups (mortality of 7.5% in both groups, adjusted HR 0.99, 95% CI: 0.72-1.35, p-value=0.94; 6.0% vs 5.2% for myocardial infarction, adjusted HR 1.19, 95% CI: 1.00-1.43, p-value=0.06). Conclusions: In a nationwide scenario, the use of a sirolimus-eluting ultrathin-strut DES portended favourable clinical outcomes.

Original language	English
Journal	EuroIntervention
Volume	16
Issue	17
Pages (from-to)	1413-1421
Number of pages	9
ISSN	1774-024X
DOIs	https://doi.org/10.4244/EIJ-D-20-00429
Publication status	Published - Apr 2021
Externally published	Yes

Access to Document

10.4244/EIJ-D-20-00429

Cite this

Buccheri, S., Sarno, G., Erlinge, D., Renlund, H., Lagerqvist, B., Grimfjärd, P., Witt, N., Yndigegn, T., Fröbert, O., Persson, J., Böhm, F., & James, S. (2021). Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). EuroIntervention, 16(17), 1413-1421. https://doi.org/10.4244/EIJ-D-20-00429

@article{66e683061293413f80015d4ba2a5d243,

title = "Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)",

abstract = "Aims: The aim of this study was to assess the real-world clinical performance of a sirolimus-eluting ultrathin-strut drug-eluting stent (DES) (Orsiro) in a large nationwide cohort of patients undergoing percutaneous coronary intervention (PCI). Methods and results: From the Swedish Coronary Angiography and Angioplasty Registry, the two-year outcomes of 4,561 patients implanted with Orsiro (Orsiro group) and 69,570 receiving other newer-generation DES (n-DES group) were analysed. The rate of definite stent thrombosis was low in both groups (0.67% and 0.83% for Orsiro and n-DES, respectively; adjusted hazard ratio [HR] 0.90, 95% confidence interval [CI]: 0.55-1.46, p-value 0.66). Restenosis was also infrequent (1.5% vs 2.0% with Orsiro and n-DES, adjusted HR 0.81, 95% CI: 0.63-1.03, p-value=0.09). The risk of target lesion revascularisation by PCI was lower in the Orsiro group (1.6% vs 2.3%, adjusted HR 0.75, 95% CI: 0.60-0.94, p-value=0.013). All-cause mortality and myocardial infarction did not show a statistically significant difference between the two groups (mortality of 7.5% in both groups, adjusted HR 0.99, 95% CI: 0.72-1.35, p-value=0.94; 6.0% vs 5.2% for myocardial infarction, adjusted HR 1.19, 95% CI: 1.00-1.43, p-value=0.06). Conclusions: In a nationwide scenario, the use of a sirolimus-eluting ultrathin-strut DES portended favourable clinical outcomes.",

author = "Sergio Buccheri and Giovanna Sarno and David Erlinge and Henrik Renlund and Bo Lagerqvist and Per Grimfj{\"a}rd and Nils Witt and Troels Yndigegn and Ole Fr{\"o}bert and Jonas Persson and Felix B{\"o}hm and Stefan James",

year = "2021",

month = apr,

doi = "10.4244/EIJ-D-20-00429",

language = "English",

volume = "16",

pages = "1413--1421",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "Europa Group",

number = "17",

}

Buccheri, S, Sarno, G, Erlinge, D, Renlund, H, Lagerqvist, B, Grimfjärd, P, Witt, N, Yndigegn, T, Fröbert, O, Persson, J, Böhm, F & James, S 2021, 'Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)', EuroIntervention, vol. 16, no. 17, pp. 1413-1421. https://doi.org/10.4244/EIJ-D-20-00429

Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). / Buccheri, Sergio; Sarno, Giovanna; Erlinge, David et al.
In: EuroIntervention, Vol. 16, No. 17, 04.2021, p. 1413-1421.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent

T2 - a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

AU - Buccheri, Sergio

AU - Sarno, Giovanna

AU - Erlinge, David

AU - Renlund, Henrik

AU - Lagerqvist, Bo

AU - Grimfjärd, Per

AU - Witt, Nils

AU - Yndigegn, Troels

AU - Fröbert, Ole

AU - Persson, Jonas

AU - Böhm, Felix

AU - James, Stefan

PY - 2021/4

Y1 - 2021/4

N2 - Aims: The aim of this study was to assess the real-world clinical performance of a sirolimus-eluting ultrathin-strut drug-eluting stent (DES) (Orsiro) in a large nationwide cohort of patients undergoing percutaneous coronary intervention (PCI). Methods and results: From the Swedish Coronary Angiography and Angioplasty Registry, the two-year outcomes of 4,561 patients implanted with Orsiro (Orsiro group) and 69,570 receiving other newer-generation DES (n-DES group) were analysed. The rate of definite stent thrombosis was low in both groups (0.67% and 0.83% for Orsiro and n-DES, respectively; adjusted hazard ratio [HR] 0.90, 95% confidence interval [CI]: 0.55-1.46, p-value 0.66). Restenosis was also infrequent (1.5% vs 2.0% with Orsiro and n-DES, adjusted HR 0.81, 95% CI: 0.63-1.03, p-value=0.09). The risk of target lesion revascularisation by PCI was lower in the Orsiro group (1.6% vs 2.3%, adjusted HR 0.75, 95% CI: 0.60-0.94, p-value=0.013). All-cause mortality and myocardial infarction did not show a statistically significant difference between the two groups (mortality of 7.5% in both groups, adjusted HR 0.99, 95% CI: 0.72-1.35, p-value=0.94; 6.0% vs 5.2% for myocardial infarction, adjusted HR 1.19, 95% CI: 1.00-1.43, p-value=0.06). Conclusions: In a nationwide scenario, the use of a sirolimus-eluting ultrathin-strut DES portended favourable clinical outcomes.

AB - Aims: The aim of this study was to assess the real-world clinical performance of a sirolimus-eluting ultrathin-strut drug-eluting stent (DES) (Orsiro) in a large nationwide cohort of patients undergoing percutaneous coronary intervention (PCI). Methods and results: From the Swedish Coronary Angiography and Angioplasty Registry, the two-year outcomes of 4,561 patients implanted with Orsiro (Orsiro group) and 69,570 receiving other newer-generation DES (n-DES group) were analysed. The rate of definite stent thrombosis was low in both groups (0.67% and 0.83% for Orsiro and n-DES, respectively; adjusted hazard ratio [HR] 0.90, 95% confidence interval [CI]: 0.55-1.46, p-value 0.66). Restenosis was also infrequent (1.5% vs 2.0% with Orsiro and n-DES, adjusted HR 0.81, 95% CI: 0.63-1.03, p-value=0.09). The risk of target lesion revascularisation by PCI was lower in the Orsiro group (1.6% vs 2.3%, adjusted HR 0.75, 95% CI: 0.60-0.94, p-value=0.013). All-cause mortality and myocardial infarction did not show a statistically significant difference between the two groups (mortality of 7.5% in both groups, adjusted HR 0.99, 95% CI: 0.72-1.35, p-value=0.94; 6.0% vs 5.2% for myocardial infarction, adjusted HR 1.19, 95% CI: 1.00-1.43, p-value=0.06). Conclusions: In a nationwide scenario, the use of a sirolimus-eluting ultrathin-strut DES portended favourable clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85105691466&partnerID=8YFLogxK

U2 - 10.4244/EIJ-D-20-00429

DO - 10.4244/EIJ-D-20-00429

M3 - Journal article

C2 - 33016880

AN - SCOPUS:85105691466

SN - 1774-024X

VL - 16

SP - 1413

EP - 1421

JO - EuroIntervention

JF - EuroIntervention

IS - 17

ER -

Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this